Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SEED INNOVATIONS LIMITED M&A Activity 2021

Apr 7, 2021

7909_rns_2021-04-07_6cc3e7f3-4a0b-48da-baf5-ac2bdc434be8.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 7302U

FastForward Innovations Limited

07 April 2021

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

7 April 2021

FastForward Innovations Ltd ("FastForward", "the Company" or, "FFWD")

Completion of Sale of Investment in EMMAC Life Sciences

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note that, further to the announcement of 10 March 2021, the sale of its investee company, EMMAC Life Sciences Limited ('EMMAC'), to Curaleaf Holdings Inc. ('Curaleaf'), has successfully been completed (the 'Transaction').

As announced, FFWD had conditionally agreed to sell its entire interest in EMMAC (comprising 6,666,667 ordinary shares and a £750,000 convertible loan note) (the 'Sale') for £5,036,459 in cash (the 'Sale Consideration') and therefore, immediately prior to completion of the Transaction, FFWD has completed  the Sale and received the Sale Consideration. The proceeds of the Sale will be used to make further investments in accordance with the Company's investing policy.

Ian Burns, Chairman of FastForward Innovations, commented: "We are pleased to note that all conditions in the sale of EMMAC to Curaleaf have been met and the transaction has completed.  We are delighted to have made a significant return on our original investment in EMMAC. This will result in us being in an enviable position of having cash totalling in excess of £6.5 million, which we aim to invest in new exciting opportunities, principally within the highly active medical cannabis, cannabinoid wellness and life sciences sectors."

**ENDS**

For further information on the Company please visit www.fstfwd.co or contact:

Ed McDermott / Lance de Jersey FastForward Innovations Ltd Email: [email protected]
James Biddle / Roland Cornish Beaumont Cornish Limited,

Nomad
Tel: +44 (0) 207 628 3396
Isabella Pierre / Damon Heath Shard Capital Partners LLP Tel: (0)207 186 9927
Catherine Leftley / Megan Dennison St Brides Partners Ltd,

Financial PR
Tel: +44 (0)207 236 1177

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DISUBUVRAUUSRAR